INFORMAZIONI SU QUESTO ARTICOLO

Cita

FIGURE 1

Expression analysis (Q-PCR) of the HERC5 (A), IFIH1 (B), and SAMD4 (C) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0. 0 and ***p<0.001
Expression analysis (Q-PCR) of the HERC5 (A), IFIH1 (B), and SAMD4 (C) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0. 0 and ***p<0.001

FIGURE 2

Expression analysis (Q-PCR) of the SEMA3A (A) and MCTP1 (B) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0.01 and ***p<0.001
Expression analysis (Q-PCR) of the SEMA3A (A) and MCTP1 (B) transcripts in different ovarian cancer cell lines. The figure presents the relative gene expression in cell lines (grey bars) with respect to the W1 cell line (white bar), which was assigned a value of 1. The values were considered significant at *p<0.05, **p<0.01 and ***p<0.001

Summary of cell lines resistance to cisplatin, paclitaxel, doxorubicin and topotecan treatment

Cell line IC50 (ng/ml)
cisplatin paclitaxel doxorubicin topotecan
W1 151 (96–216)1 3,37 (3,18–3,62)1 13,6 (9,1–18,0)1 2,03 (1,94–2,11)1
A2780 439 (283–565)2,9 ↑* 3,43 (1,91–4,73)1,02 ↑ 19,79 (12,52–24,44)1,46 ↑ 3,13 (1,48–4,71) 1,54 ↑
SKOV-3 890 (595–1222)5,8 ↑** 0,784 (0,73–0,84)4,30 ↑** 17,76 (13,7–22,84)1,31 ↑ 51,9 (40,34–60,71)25,6 ↑***
OVCAR-3 2613 (2125–2884)17,3 ↑*** 458 (372–594)136 ↑*** 354 (203–571)26 ↑** 398 (283–505) 196↑***
PEA1 2737 (2031–3763)18,1 ↑** 5,66 (3,25–9,07)1,68 ↑ 81 (72–90)5,96 ↑** 29 (19,2–46,9)14,3 ↑**
PEA2 2469 (2426–2557)16,4 ↑*** 6,88 (4,31–8,38)2,04 ↑* 173 (148–195)12,7 ↑** 132 (79–188)65 ↑**
PEO23 2171 (1839–2438)14,4 ↑*** 1404 (1000–1600)417 ↑*** 275 (198–375)20,2 ↑*** 498 (300–750)245 ↑**

Characterization of cell lines used in this study

Cell line Origin Chemotherapy Treatment outcome
W1 tumor tissue, ovarian serous adenocarcinoma No N/A
A2780 tumour tissue, ovarian endometrioid adenocarcinoma No N/A
SKOV-3 ascites, ovarian serous adenocarcinoma ThioTEPA ineffective
OVCAR-3 ascites, ovarian serous adenocarcinoma, high grade cyclophosphamide, DOX, CIS ineffective
PEA1 pleural effusion, serous adenocarcinoma, high grade No N/A
PEA2 ascites, serous adenocarcinoma, high grade CIS, Prednimustine ineffective
PEA O23 ascites, serous adenocarcinoma, low grade CIS, chlorambucil ineffective

Oligonucleotide sequences used for Q-PCR analysis

Transcript Sequence (5′-3′ direction) ENST number Product size
MCTP1 F AGAACCTCAACCCTGTGTGG 00000312216 123 bp
R AGGCTGAGCCCATAAAGTCA
IFIH1 F GGGGCATGGAGAATAACTCA 00000263642 132 bp
R TGCCCATGTTGCTGTTATGT
SAMD4 F CCAAAGGTGCAAGACACAAA 00000251091 146 bp
R CGGAGTCAGGATCATCTGGT
HERC5 F CTTCCTGCATGTGGTTTCCT 00000264350 128 bp
R AAACAGTGCCAGTGGGAAAG
SEMA3A F TGTTGGAGCAAAGGATCACA 00000265362 109 bp
R AGCCCACTTGCATTCATCTC
GAPDH F GAAGGTGAAGGTCGGAGTCA 00000229239 199 bp
R GACAAGCTTCCCGTTCTCAG
β-actin F TCTGGCACCACACCTTCTAC 00000331789 169 bp
R GATAGCACAGCCTGGATAGC
HPRT1 F CTGAGGATTTGGAAAGGGTG 00000298556 156 bp
R AATCCAGCAGGTCAGCAAAG
B2M F CGCTACTCTCTCTTTCTGGC 00000558401 133 bp
R ATGTCGGATGGATGAAACCC
eISSN:
2544-3577
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Life Sciences, Molecular Biology, Biochemistry